Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14655617 | Publishing Date : 03-Sep-2019 | No. of pages : 145
Detailed TOC of Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antipsychotics - Market size and forecast 2018-2023
• Non-antipsychotics - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Development of novel therapeutics
• Increasing strategic alliances
• Growing number of research studies to understand genetic root cause of
• Tourette’s syndrome
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• H. Lundbeck AS
• Johnson & Johnson Services Inc.
• Mylan NV
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca Plc - Vendor overview
Exhibit 49: AstraZeneca Plc - Business segments
Exhibit 50: AstraZeneca Plc - Organizational developments
Exhibit 51: AstraZeneca Plc - Geographic focus
Exhibit 52: AstraZeneca Plc - Key offerings
Exhibit 53: AstraZeneca Plc - Key customers
Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 55: Boehringer Ingelheim International GmbH - Business segments
Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 60: Boehringer Ingelheim International GmbH - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: H. Lundbeck AS - Vendor overview
Exhibit 69: H. Lundbeck AS - Business segments
Exhibit 70: H. Lundbeck AS - Organizational developments
Exhibit 71: H. Lundbeck AS - Geographic focus
Exhibit 72: H. Lundbeck AS - Key offerings
Exhibit 73: H. Lundbeck AS - Key customers
Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 75: Johnson & Johnson Services Inc. - Business segments
Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 78: Johnson & Johnson Services Inc. - Segment focus
Exhibit 79: Johnson & Johnson Services Inc. - Key offerings
Exhibit 80: Johnson & Johnson Services Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 95: Pfizer Inc. - Vendor overview
Exhibit 96: Pfizer Inc. - Business segments
Exhibit 97: Pfizer Inc. - Organizational developments
Exhibit 98: Pfizer Inc. - Geographic focus
Exhibit 99: Pfizer Inc. - Segment focus
Exhibit 100: Pfizer Inc. - Key offerings
Exhibit 101: Pfizer Inc. - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors